Prostate Cancer (Issue 1) | Special Reports

September 30, 2015

Androgen deprivation therapy has been the standard of care for patients with advanced prostate cancer (PC), because these agents inhibit cancer progression in the early stages of disease.

September 29, 2015

A subanalysis of the ALSYMPCA trial suggests that chemotherapy can be safely administered after treatment with radium-223 in patients with metastatic CRPC and bone metastasis.

September 29, 2015

Neal D. Shore, MD, FACS, Atlantic Urology Clinics, discusses glypican-1 as a biomarker for prostate cancer.

September 28, 2015

Howard M. Sandler, MD, MS, FASTRO, Cedars Sinai, discusses patient benefit and toxicities of a phase III study of docetaxel with hormonal and radiation therapy of patients with prostate cancer.

September 25, 2015

Fred Saad, MD, FRCS, University of Montreal, discusses the benefit of radium-223 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

September 24, 2015

Targeted Oncology spoke with two leading experts in the prostate cancer field about the range of available treatments and their current applications in men with mCRPC.

September 22, 2015

Circulating tumor cells (CTCs) have been recognized as a potential source of prostate cancer seeding to distant metastatic sites (typically bone) for over a century.

September 22, 2015

Bone metastases in metastatic castration-resistant prostate cancer (mCRPC) can invade a range of sites in the skeleton where they precipitate a spectrum of pathological processes that increase morbidity, negatively affect quality of life, and decrease survival.